Management of Psoriatic Arthritis After Failure of First‑Line Therapies

Pharmacologic Considerations

Hydroxychloroquine is not recommended for psoriatic arthritis because it can trigger psoriasis flares and has no proven efficacy for joint disease. 1
Chronic systemic corticosteroids are discouraged in psoriatic arthritis due to the risk of post‑steroid psoriasis flare and the lack of a disease‑modifying effect on joint damage. 2
Etanercept provides lower or slower improvement of skin lesions compared with monoclonal TNF‑α antibodies (adalimumab, infliximab) and is inferior to IL‑17 and IL‑12/23 inhibitors for cutaneous disease. 2
Generalized edema or swelling signals ongoing active synovitis even when C‑reactive protein (CRP) has improved; CRP alone does not define remission in psoriatic arthritis. 1

Discontinue hydroxychloroquine immediately because it is contraindicated in psoriatic arthritis and may worsen skin involvement. 1
Taper prednisone to the lowest feasible dose (≤10 mg/day) for a short period (<3 months) and discontinue as soon as the new biologic achieves disease control. 2

IL‑17 inhibitors (secukinumab 150–300 mg monthly or ixekizumab 80 mg every 2–4 weeks) and IL‑12/23 inhibitor (ustekinumab 45–90 mg every 12 weeks) are first‑line biologic choices for patients with active psoriatic arthritis and clinically significant skin disease. 2
These agents demonstrate superior skin efficacy compared with etanercept and are highly effective for peripheral arthritis. 2

Methotrexate (15–25 mg weekly) is the preferred conventional DMARD for psoriatic arthritis, especially when skin involvement is present, and should be combined with a biologic for optimal joint outcomes. 2

Reassess disease activity every 1–3 months using tender/swollen joint counts, patient global assessment, and functional measures to ensure the target of remission or minimal disease activity is being met. 1

Prolonged systemic corticosteroid use (>1–2 years) increases the risk of psoriasis flare upon withdrawal and contributes to cumulative toxicity, including osteoporosis, fractures, and cardiovascular disease. 2

The American College of Rheumatology recommends starting with a TNF inhibitor (such as etanercept, adalimumab, or infliximab) over oral small molecules, IL-17 inhibitors, or IL-12/23 inhibitors for treatment-naïve patients with active psoriatic arthritis, unless the patient has severe psoriasis, contraindications to TNF inhibitors, or prefers oral therapy 3, 4
Consider IL-17 or IL-12/23 inhibitors as first-line therapy if the patient has severe psoriasis (defined as PASI ≥12 and BSA ≥10) 3, 4
Consider oral small molecules (methotrexate preferred) as first-line therapy if the patient has contraindications to TNF inhibitors, prefers oral medications, or lacks severe psoriasis/PsA 3, 4

Switch to a TNF inhibitor over another oral small molecule, IL-17 inhibitor, or IL-12/23 inhibitor if active PsA persists despite adequate trial of oral small molecules 5, 6
Consider IL-17 or IL-12/23 inhibitors instead if severe psoriasis is present 5, 6
Consider switching to IL-12/23 inhibitor over another oral small molecule if concomitant active IBD exists 5, 6

Methotrexate is the preferred conventional DMARD, especially when clinically relevant skin involvement is present 3, 4, 7
IL-12/23 inhibitors offer less frequent administration compared to other biologics 3, 4
IL-12/23 inhibitors are preferred if concomitant IBD is present 6, 3, 4

The primary goal is achieving remission or, alternatively, minimal/low disease activity through regular monitoring and appropriate treatment adjustment 8, 7
Target abrogation of inflammation as the critical component to maximize long-term health-related quality of life, control symptoms, prevent structural damage, and normalize function 8, 7
Reassess disease activity regularly and adjust therapy if treatment targets are not met 8, 7
Account for comorbidities (obesity, metabolic syndrome, cardiovascular disease, depression) when selecting treatment, considering safety profiles of individual agents 9, 7